| HLA typing |
Source: PubMed=10359208
| Class I | | HLA-A | A*02,02 | | HLA-B | B*35,60 | | HLA-C | C*03,04 | | Class II | | HLA-DQ | DQA1*01:02,01:02 | | DQB1*06:02,06:04 | | HLA-DR | DRB1*13:02,15 |
Source: PubMed=12836015
| Class I | | HLA-A | A*02:01,02:01 | | HLA-B | B*35,40 | | Class II | | HLA-DQ | DQB1*06:02,06:04:01 | | HLA-DR | DRB1*13:02,15:01:01 |
|
|---|
| Publications | PubMed=9384677
Guckel B., Lindauer M., Rudy W., Habicht A., Siebels M., Kaul S., Bastert G., Meuer S.C., Moebius U.
CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.
Cytokines Mol. Ther. 1:211-221(1995) PubMed=10359208; DOI=10.1038/sj.cgt.7700050
Guckel B., Meyer G.C., Rudy W., Batrla R., Meuer S.C., Bastert G., Wallwiener D., Moebius U.
Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.
Cancer Gene Ther. 6:228-237(1999) PubMed=10359214; DOI=10.1038/sj.cgt.7700054
Meyer G.C., Batrla R., Rudy W., Meuer S.C., Wallwiener D., Guckel B., Moebius U.
Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation.
Cancer Gene Ther. 6:282-288(1999) PubMed=12836015; DOI=10.1007/s00432-003-0445-7
Kayser S., Watermann I., Rentzsch C., Weinschenk T., Wallwiener D., Guckel B.
Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
J. Cancer Res. Clin. Oncol. 129:397-409(2003) PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349
Guckel B., Stumm S., Rentzsch C., Marme A., Mannhardt G., Wallwiener D.
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Cancer Immunol. Immunother. 54:129-140(2005) |
|---|
